Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Wong DK"" wg kryterium: Autor


Tytuł:
Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study.
Autorzy:
Kan K; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Hui RW; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China. .; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China. .
Mak LY; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China. .; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Oct 06; Vol. 23 (1), pp. 348. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Humans ; Male ; Middle Aged ; Aged ; Female ; Retrospective Studies ; Longitudinal Studies ; Hepatitis B Antibodies/therapeutic use ; Hepatitis B virus/genetics ; DNA, Viral ; Hepatitis B e Antigens
Czasopismo naukowe
Tytuł:
A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use.
Autorzy:
Gizaw A; Virginia Commonwealth University, Richmond, Virginia, USA.
King WC; University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Hinerman AS; University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Chung RT; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Lisker-Melman M; Washington University School of Medicine and John Cochran VA Medical Center, St. Louis, Missouri, USA.
Ghany MG; National Institute of Health, Bethesda, Maryland, USA.
Khalili M; University of California San Francisco, San Francisco, California, USA.
Jain MK; University of Texas Southwestern and Parkland Health & Hospital System, Dallas, Texas, USA.
Graham J; Biobehavioral Research Lab, Virginia Commonwealth University School of Nursing.
Swift-Scanlan T; Biobehavioral Research Lab, Virginia Commonwealth University School of Nursing.
Kleiner DE; National Cancer Institute, Bethesda, Maryland, USA.
Sulkowski M; Johns Hopkins University, Baltimore, Maryland, USA.
Wong DK; University Health Network, Toronto, Ontario, Canada.
Sterling RK; Virginia Commonwealth University, Richmond, Virginia, USA.
Pokaż więcej
Corporate Authors:
HIV-HBV Cohort Study of the Hepatitis B Research Network
Źródło:
HIV medicine [HIV Med] 2023 Jan; Vol. 24 (1), pp. 55-74. Date of Electronic Publication: 2022 May 16.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
HIV Infections*/complications
HIV Infections*/drug therapy
Coinfection*/drug therapy
Hepatitis B*/epidemiology
Hepatitis B*/drug therapy
Humans ; Adult ; Male ; Middle Aged ; Female ; Tenofovir/adverse effects ; Hepatitis B virus ; Cohort Studies ; Prospective Studies ; Prevalence ; Kidney/physiology ; Bone Remodeling
Czasopismo naukowe
Tytuł:
Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Autorzy:
Coffin CS; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Haylock-Jacobs S; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Doucette K; Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Ramji A; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Ko HH; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Wong DK; Department of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada.
Elkhashab M; Toronto Liver Centre, Toronto, ON M6H 3M1, Canada.
Bailey R; Bailey Health Clinic, Edmonton, AB T5H 4B9, Canada.
Uhanova J; Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Minuk G; Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Tsoi K; Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.
Wong A; Department of Medicine, University of Saskatchewan, Regina, SK S7N 5A2, Canada.
Ma MM; Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Tam E; Pacific Gastroenterology Associates, Vancouver, BC V6Z 2K5, Canada.
Brahmania M; Multi Organ Transplant Unit, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 3K7, Canada.
Nudo C; Cité-de-la-Santé de Laval, Laval, QC H7M 3L9, Canada.
Zhu J; Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Lowe CF; Division of Medical Microbiology, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada.
Osiowy C; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.
Lethebe BC; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Congly SE; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Chan EKH; Janssen Global Services LC, Raritan, NJ 08869, USA.
Villasis-Keever A; Janssen Global Services LC, Raritan, NJ 08869, USA.
Sbarigia U; Janssen Pharmaceuticals NV, 2340 Beerse, Belgium.
Cooper CL; Department of Medicine, Division of infectious Diseases, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Fung S; Department of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Nov 29; Vol. 14 (12). Date of Electronic Publication: 2022 Nov 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B, Chronic*
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Adult ; Humans ; Female ; Middle Aged ; Male ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Retrospective Studies ; Hepatitis B e Antigens ; Antigens, Surface ; Cohort Studies ; Cross-Sectional Studies ; Canada/epidemiology ; Antiviral Agents/therapeutic use ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/complications ; DNA, Viral
Czasopismo naukowe
Tytuł:
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
Autorzy:
Liem KS; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Chi H; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Fung S; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
Wong DK; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
Yim C; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
Noureldin S; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
Chen J; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
de Man RA; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Sarowar A; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
Feld JJ; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.; McLaughlin-Rotman Centre for Global Health, Toronto, Ontario, Canada.
Hansen BE; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Hou J; Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Peng J; Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Janssen HLA; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2022 Nov; Vol. 29 (11), pp. 986-993. Date of Electronic Publication: 2022 Sep 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Alanine Transaminase ; Antiviral Agents/therapeutic use ; DNA, Viral ; Female ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Male ; Prospective Studies ; Recurrence
Czasopismo naukowe
Tytuł:
Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.
Autorzy:
Mitsui Y; Department of Urology Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan. .; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA. .
Chang I; Department of Oral Biology, Yonsei University College of Density, Seoul, South Korea.; Department of Urology, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan.
Fukuhara S; Department of Urology, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan.
Hiraki M; Department of Urology Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan.
Arichi N; Department of Urology Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan.
Yasumoto H; Department of Urology Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan.
Hirata H; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Yamamura S; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Shahryari V; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Deng G; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Wong DK; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Majid S; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Shiina H; Department of Urology Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan.
Dahiya R; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA.
Tanaka Y; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, Bldg 42 Rm 109, San Francisco, CA, 94121, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Jul 25; Vol. 22 (1), pp. 813. Date of Electronic Publication: 2022 Jul 25.
Typ publikacji:
Published Erratum
Tytuł:
Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma.
Autorzy:
Jia JA; Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, 200438, China.; Department of Laboratory Medicine, The 901th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Hefei, 230031, China.
Zhang S; Centre for Computational Systems Biology, School of Mathematical Sciences, Fudan University, Shanghai, 200433, China.
Bai X; Molecular and Computational Program, Department of Biological Sciences, University of Southern California, 1050 Childs Way, Los Angeles, 90089, USA.
Fang M; Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, 200438, China.
Chen S; Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, 200438, China.
Liang X; Department of Computer Science, Fudan University, Shanghai, 200433, China.
Zhu S; Department of Computer Science, Fudan University, Shanghai, 200433, China.; Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, 200433, China.
Wong DK; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Zhang A; Department of Medicine, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518033, China.
Feng J; Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, 200433, China.; Department of Computer Science, University of Warwick, Coventry, CV4 7AL, UK.
Sun F; Molecular and Computational Program, Department of Biological Sciences, University of Southern California, 1050 Childs Way, Los Angeles, 90089, USA. .
Gao C; Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai, 200438, China. .; Clinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2022 Jun 28; Vol. 19 (1), pp. 114. Date of Electronic Publication: 2022 Jun 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*
Hepatitis B Surface Antigens/genetics ; Hepatitis B virus/genetics ; Humans ; Logistic Models ; Nucleotides ; Quasispecies
Czasopismo naukowe
Tytuł:
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Cheung KS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong. .; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2021 Mar 17; Vol. 21 (1), pp. 123. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Hepatitis B Core Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Japan ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients.
Autorzy:
Liem KS; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wong DK; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Fung S; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Zahirieh A; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Yim C; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Zanjir WR; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.; McLaughlin-Rotman Centre for Global Health, Toronto, ON, Canada.
Hansen BE; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Janssen HLA; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2021 Jan; Vol. 28 (1), pp. 51-60. Date of Electronic Publication: 2020 Oct 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Humans ; Kidney/physiology ; Longitudinal Studies ; Renal Dialysis ; Tenofovir/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
Ko KL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
To WP; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2020 Sep 15; Vol. 14 (5), pp. 665-668.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/etiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/etiology
Antiviral Agents/therapeutic use ; Biomarkers ; DNA, Viral ; Female ; Guanine/analogs & derivatives ; Hepatitis B Core Antigens ; Hepatitis B e Antigens ; Hepatitis B virus ; Humans ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients.
Autorzy:
Chua CG; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, Canada.
Mehrotra A; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
Mazzulli T; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.; Department of Microbiology, Mount Sinai Hospital, University Health Network, Toronto, Canada.
Wong DK; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
Janssen HLA; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
Gehring AJ; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. .; Institute of Medical Sciences, University of Toronto, Toronto, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Jul 09; Vol. 10 (1), pp. 11344. Date of Electronic Publication: 2020 Jul 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
CD8-Positive T-Lymphocytes/*immunology
Hepatitis B Antigens/*immunology
Hepatitis B, Chronic/*immunology
Adult ; Aged ; CD8-Positive T-Lymphocytes/cytology ; Cytokines/immunology ; Enzyme-Linked Immunospot Assay ; Female ; Hepatitis B virus ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
Autorzy:
To WP; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Liu F; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Lai CL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2019 Dec; Vol. 26 (12), pp. 1473-1480. Date of Electronic Publication: 2019 Sep 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular/*blood
Carcinoma, Hepatocellular/*etiology
Hepatitis B Core Antigens/*blood
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*complications
Liver Neoplasms/*blood
Liver Neoplasms/*etiology
Adult ; Biomarkers ; Carcinoma, Hepatocellular/diagnosis ; Disease Susceptibility ; Female ; Hepatitis B Core Antigens/immunology ; Hepatitis B e Antigens/immunology ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/immunology ; Hepatitis B, Chronic/virology ; Humans ; Incidence ; Liver Neoplasms/diagnosis ; Male ; Middle Aged ; Proportional Hazards Models ; ROC Curve ; Risk Factors ; Seroconversion
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies